RCKTW
HEALTHCARERocket Pharmaceuticals Inc - Warrants (02/09/2026)
$0.01-0.00 (-1.01%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RCKTW Today?
No stock-specific AI insight has been generated for RCKTW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.01$0.08
$0.01
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume400
Avg Volume (10D)—
Shares Outstanding—
RCKTW News
20 articles- Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush SaysYahoo Finance·May 8, 2026
- Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent ProgressYahoo Finance·May 7, 2026
- Rocket to sell PRV for $180m to advance gene therapy pipelineHospitalmanagement·Apr 29, 2026
- Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review VoucherYahoo Finance·Apr 28, 2026
- RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare DiseaseYahoo Finance·Mar 30, 2026
- Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADIYahoo Finance·Mar 29, 2026
- Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene TherapyYahoo Finance·Mar 29, 2026
- Promising Penny Stocks To Consider In March 2026Yahoo Finance·Mar 27, 2026
- Rocket Pharmaceuticals Wins FDA Accelerated Approval for KRESLADI Gene Therapy in Severe LAD-I KidsMarketbeat·Mar 27, 2026
- Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADIProactive Investors·Mar 27, 2026
- Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)Yahoo Finance·Mar 27, 2026
- Rocket Pharmaceuticals to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 23, 2026
- Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector RecoveryYahoo Finance·Feb 19, 2026
- Neurvati Neurosciences Appoints Carlos Martin as Chief Commercial OfficerYahoo Finance·Nov 13, 2025
- Leukocyte Adhesion Deficiency Market Analysis and Forecast, 2025-2035, Featuring Rocket Pharmaceuticals, Avalo Therapeutics, Orpha Labs, and AUG TherapeuticsYahoo Finance·Nov 12, 2025
- Rocket Pharmaceuticals: Q3 Earnings SnapshotYahoo Finance·Nov 6, 2025
- Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent ProgressYahoo Finance·Nov 6, 2025
- Is Rocket Pharmaceuticals (RCKT) One of the Best NASDAQ Stocks Under $5 to Buy Now?Yahoo Finance·Oct 26, 2025
- RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene TherapyYahoo Finance·Oct 15, 2025
- Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)Yahoo Finance·Oct 14, 2025
All 20 articles loaded
Price Data
Open$0.01
Previous Close$0.01
Day High$0.01
Day Low$0.01
52 Week High$0.08
52 Week Low$0.01
52-Week Range
$0.01$0.08
$0.01
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume400
Avg Volume (10D)—
Shares Outstanding—
About Rocket Pharmaceuticals Inc - Warrants (02/09/2026)
Rocket Pharmaceuticals, Inc., is a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The company is headquartered in Cranbury, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—